MultiCell Technologies Inc (MCET)

[Euripides90]

Found this:Co. still has patents,potential:article makes clear the risks but what if something's brewin': anyway the O/S was updated this Jan. 21 as under 5B regardless of what someone keeps claiming as double that, check OTC markets. That has turned over many times by manipulators last few days, surging to down to likely bounce next week. No one's denying it's high risk but this is interesting, might someone know something?

MCET (MultiCell Technologies) Surging Higher on Fa N2-4 immortalized Human Hepatocytes Cell Lines Patent 1
BY BOE RIMES ON FEBRUARY 16, 2021

https://microcapdaily.com/biotech-sleeper-mcet-multicell-technologies-surging-higher-as-its-fa-n2-4-immortalized-human-hepatocytes-cell-lines-patent/130352/

Some new blood could be coming into this:

...the Company may still own a few patents including the Fa N2-4 immortalized Human Hepatocytes Cell Lines.

Back in 2009 MCET was granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays.

MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.

...MultiCell holds two patents on novel strategies for isolation of adult human liver cells, and cell clusters or doublets, invented by Dr. Ronald A. Faris, Senior Vice President and Chief Scientific Officer of MutliCell and Director of Research with Rhode Island Hospital. Obtaining stem cells from adult tissues avoids the ethical issues and the contamination issues associated with embryonic or fetal stem cells. Liver stem cells may play a key role in transplantation for tissue regeneration and therapeutic use including the clinical management of metabolic liver disorders and heart disease as well as potential diagnostic applications. The use of liver stem cells to treat diseases, such as Hepatitis C, may greatly enhance quality of life and avoid costly whole organ liver transplantation. MultiCell believes its patented stem cell techniques are unique within the cell therapy market.

MCET (MultiCell Technologies) has been heating up and running northbound in recent weeks running out of the triple zeroes and trading several hundred million shares a day with a recent high of $0.0016 per share. The stock has been under heavy accumulation recently and volume has picked up substantially

My search revealed that iHub Member MCETDreamer post #45009 today picked this up today too but I didn't notice it, independently
found same thing.

See also this Member Post from last month on new younger CEO and C V: TPX Tuesday, 01/05/21 11:57:08 AM
Re: None 0
Post # 43632 of 45225

NEW CEO Edward Sigmond, 57 of Multicell Technologies and Multicell Immunotherapeutics, Inc.

Edward Sigmond, 57 Independent Director, MultiCell Technologies, Inc.

Mr. Edward Sigmond is Partner at Sigmond & Johnson, Inc., Independent Director at MultiCell Technologies, Inc., President at Kestrel Holdings, Inc., Chairman, CEO & Head-Investor Relations at The Great American Food Chain, Inc., Managing Partner & Owner at The Elbow Room, and a Director & Partner at Na Zdravi Ventures as. He is on the Board of Directors at MultiCell Technologies, Inc. and Na Zdravi Ventures as.

Older Patent asset might be coming into its time:
https://www.investorvillage.com/smbd.asp?mb=6619&mn=42&pt=msg&mid=13466646